(Q46694974)

24 December 2017

title

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer (English)

1 reference

24 December 2017

author name string

Hideaki Miyake

series ordinal

1

1 reference

24 December 2017

Isao Hara

series ordinal

2

1 reference

24 December 2017

Hiroshi Eto

series ordinal

3

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

published in

BJU International

1 reference

24 December 2017

volume

96

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

791-795

1 reference

24 December 2017

Management of hormone refractory prostate cancer: current standards and future prospects

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Chemotherapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Nilutamide: possible utility as a second-line hormonal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Secondary hormonal therapies in the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

TR3 orphan nuclear receptor mediates apoptosis through up-regulating E2F1 in human prostate cancer LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05766.X

10.1111/J.1464-410X.2005.05766.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017